Bacopa Monnieri The Alzheimer's Disease Prevention Food
Upcoming SlideShare
Loading in...5
×
 

Bacopa Monnieri The Alzheimer's Disease Prevention Food

on

  • 806 views

Brahmi is a perennial, creeping herb whose habitat includes wetlands and muddy shores. The leaves of this plant are succulent and relatively thick. Leaves are oblanceolate and are arranged oppositely ...

Brahmi is a perennial, creeping herb whose habitat includes wetlands and muddy shores. The leaves of this plant are succulent and relatively thick. Leaves are oblanceolate and are arranged oppositely on the stem. The flowers are small and white, with four or five petals. Its ability to grow in water makes it a popular aquarium plant. It can even grow in slightly brackish conditions. Propagation is often achieved through cuttings. It commonly grows in marshy areas throughout India, Nepal, Sri Lanka, China, Taiwan, and Vietnam, and is also found in Florida, Hawaii and other southern states of the USA where it can be grown in damp conditions by the pond or bog garden.

Brahmi is known botanicaly as Bacopa monnieri. Brahmi is a nervine tonic that enhances learning, academic performance and improves mental ability. It acts as an anti anxiety agent and is used in several mental disorders. It also calms restlessness in children. Brahmi significantly improves the cognitive ability including an accelerated rate of learning and enhanced memory. These effects are optimized after a 12 week period. Bacopa monnieri extract was found to reduce beta amyloid deposits in mice with Alzheimer's disease. Taken regularly, Brahmi might reduce the chances of developing AD.

Brahmi is an Ayurvedic herb that has been used for several thousand years as a brain tonic, to enhance intellect, treat psychiatric illness, epilepsy, insomnia and as an anti stress adaptogenic herb. Evidence of cognitive activator activity from animal models of learning is positive and clinical studies have produced excellent and encouraging results. Brahmi has potent antioxidant activity, which appears to be a result of both direct free radical scavenging activity and increasing endogenous antioxidant systems in the brain and liver. Brahmi has a long history of use as a brain tonic. Results from scientific studies suggest that it may enhance memory and cognitive function and reduce anxiety with long-term use.

Statistics

Views

Total Views
806
Views on SlideShare
806
Embed Views
0

Actions

Likes
0
Downloads
13
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Bacopa Monnieri The Alzheimer's Disease Prevention Food Bacopa Monnieri The Alzheimer's Disease Prevention Food Document Transcript

  • Brahmi (Bacopa Monnieri) www.bacopa-monnieri.us Brahmi is a perennial, creeping herb whose habitat includes wetlands and muddy shores. The leaves of this plant are succulent and relatively thick. Leaves are oblanceolate and are arranged oppositely on the stem. The flowers are small and white, with four or five petals. Its ability to grow in water makes it a popular aquarium plant. It can even grow in slightly brackish conditions. Propagation is often achieved through cuttings. It commonly grows in marshy areas throughout India, Nepal, Sri Lanka, China, Taiwan, and Vietnam, and is also found in Florida, Hawaii and other southern states of the USA where it can be grown in damp conditions by the pond or bog garden. Brahmi is known botanicaly as Bacopa monnieri. Brahmi is a nervine tonic that enhances learning, academic performance and improves mental ability. It acts as an anti anxiety agent and is used in several mental disorders. It also calms restlessness in children. Brahmi significantly improves the cognitive ability including an accelerated rate of learning and enhanced memory. These effects are optimized after a 12 week period. Bacopa monnieri extract was found to reduce beta amyloid deposits in mice with Alzheimers disease. Taken regularly, Brahmi might reduce the chances of developing AD. Brahmi is an Ayurvedic herb that has been used for several thousand years as a brain tonic, to enhance intellect, treat psychiatric illness, epilepsy, insomnia and as an anti stress adaptogenic herb. Evidence of cognitive activator activity from animal models of learning is positive and clinical studies have produced excellent and encouraging results. Brahmi has potent antioxidant activity, which appears to be a result of both direct free radical scavenging activity and increasing endogenous antioxidant systems in the brain and liver. Brahmi has a long history of use as a brain tonic. Results from scientific studies suggest that it may enhance memory and cognitive function and reduce anxiety with long-term use.When will it start to work? Studies suggest that 12 weeks’ ( 3 months) continual use is required for benefitson cognitive function to become apparent.Are there any safety issues? Information from traditional sources suggests that brahmi is well tolerated atthe usual therapeutic doses. (Interact with us/ Send us any queries on facebook at facebook.com/brahmi.bacopa) www.bacopa-monnieri.us
  • Brahmi in Alzheimers disease management & preventionThere are number of research reports that confirm the beneficial properties of Brahmi in managingAlzheimers disease. Brahmi at best could slow down the degeneration of brain and improve cognition &memory in patents. It is definitely worth a try. As a preventive treatment for Alzheimers disease it could beuseful if Brahmi is taken on a regular basis. This is particularly helpful if someones close blood relatives haveor had Alzheimers disease or other types of dementia. In normal persons Brahmi does seem to improvememory, mental alertness, intellectual capacity and overall professional & academic performance. The wikipedia information on BrahmiLaboratory studies on rats indicate that extracts of the Brahmi plant improves memory capacity. Recentstudies suggest that Brahmi may improve intellectual activity. The sulfhydryl and polyphenol components ofBrahmi extract have also been shown to impact the oxidative stress cascade by scavenging reactive oxygenspecies, inhibiting lipoxygenase activity and reducing divalent metals. This mechanism of action may explainthe effect of Brahmi extract in reducing beta amyloid deposits in mice with Alzheimers disease. In a studyconducted on rats (J. Ethnopharmacol, 2009), a model was conducted where Alzheimers disease is inducedto rats. The rats were afterwards given Brahmi extract to determine its effects against Alzheimers disease.The test showed that rats given a dose of up to 80 mg/kg of Brahmi extract had improved cognitive capabilityand mitigated the further reduction of brain neurons. Brahmi could increase the quality of life of AD patients toa very high degree though it remains to be seen if Brahmi could offer a cure for Alzheimers disease. Takenwell in advance Brahmi might help prevent/delay Alzheimers disease.http://en.wikipedia.org/wiki/Bacopa_monnieri Swinburne University of Technologys Brain Sciences Institute John Street, Hawthorn,Victoria, Australia 3122Research & trials at Swinburne University of Technologys Brain Sciences Institute (funded byAustralian Government) established scientific validity of Brahmi (Bacopa monnieri ) for theprevention and treatment of Alzheimers and dementia. Swinburne’s Professor Dr.Con Stough is thedirector of the NICM Collaborative Center for Natural Medicines and Neurocognition, which is responsible fora range of trials to improve the research behind alternative medicines. Other collaborators in theneurocognition research are the University of Western Australia, Melbournes Alfred Hospital and CDRAustralia. Two Brahmi trials have been done over 90 days with double-blind, randomized control techniquesusing a special brahmi extract. The results have shown improvements in working memory, particularly spatialmemory accuracy.According to Swinburne’s Professor Dr.Con Stough and Research Fellow with AlzheimersAustralia Dr Maree Farrow "For thousands of years Ayurvedic practitioners in India have used an aquaticplant known as brahmi (Bacopa monnieri) to enhance intelligence and mental functioning. Now, Westernmedicine is examining the herbs potential to delay or treat dementia"Dr Farrow says Alzheimers Australia supports research into both pharmaceutical and natural treatments todevelop products that prove safe and effective. She says people with Alzheimers and their families aredesperate for effective treatments. Despite claims on some products about the benefits of vitamin E andGinkgo biloba, she says clinical trials have not shown conclusive results in treating already establishedAlzheimers disease, although some research suggests these supplements may have a role in delaying itsonset. If we can treat cognitive decline in the early stages then we may be able to prevent or delay moreserious cognitive impairment. Intelligence does slow and decay over time as a natural part of the agingprocess,” Professor Stough says. He says not every forgotten name or misplaced item is a sign ofAlzheimers disease. As people age their brains shrink and become less efficient. It does take longer toprocess new information and certain aspects of memory do fail. But Alzheimers dementia is a specificdisease of the brain, although science has not yet determined the exact cause; most of what is known comesfrom autopsy examinations of sufferers.The findings include inflammation of the brain, deposits of beta amyloid, traces of heavy metals andsigns of oxidative stress. Professor Stough says research suggests that Brahmi’s mechanism ofaction acts on all of these. It has an anti-inflammatory effect, is an antioxidant and collates andremoves heavy metals and beta amyloid. Professor Andrew Scholey, head of the BSI’s Herbal andNutritional Medicine Research Unit at Swinburne and who oversees many of the clinical trials, says thathistorically the field has struggled to gain scientific credibility. However, Swinburne’s trials are performed tostandards that provide acceptance within the mainstream scientific community. Being able to capture thetherapeutic cognitive benefits of a product in healthy adults provides ‘proof of concept’ and provides agateway for full-blown clinical trials in other, less healthy populations. Two brahmi trials have been done
  • over 90 days with double-blind, randomized control techniques using a special brahmi extract.The results have shown improvements in working memory, particularly spatial memory accuracy.A 50-day trial of a particular pine bark extract supplement for men aged 50 to 65 years has alsoshown improved speed in spatial working memory and immediate recognition tasks, along with atrend towards lower systolic blood pressure. Southern Cross University, NSW, AustraliaThis thesis investigated the efficacy and safety of Bacopa monnieri in improving memory in aging Australiansover the age of 55 years. A review of the literature showed that memory impairment and dementia areincreasingly prevalent in the current demographic climate of an ageing population. As well as the pathologicalcognitive loss of neurodegenerative disease, many older persons are experiencing memory loss as part ofthe physiological process of ageing.Bacopa monnieri is a herbal medicine used since antiquity in the traditional Ayurvedic medical system ofIndia for its cognitive enhancing effects. A number of pre-clinical and clinical studies support this traditionalusage. Laboratory studies have demonstrated antioxidant and cholinergic actions in the brain as well asimproved memory and cognitive performance in animal models. Human trials of Bacopa have alsodemonstrated improved memory performance.This studys replicated findings of beneficial effects on human memory have promising implications forBacopa’s potential use in dementia. This is especially so, given its demonstrated antioxidant and cholinergicactions, because dementia is associated with both oxidative damage and depletion of acetylcholine. Theside-effects observed in this study lend further weight to previous findings of a cholinergic effect of Bacopa.Animal studies have demonstrated a cholinergic action, though more research is needed to further establisha cholinergic effect for Bacopa in humans, and to identify other possible mechanisms of action as well. Giventhat even modest postponement of dementia symptoms would have enormous benefits forsufferers and for society, the identification of cognitive enhancing agents is an important pursuit.Bacopa monnieri is approved for over the counter sale in Australia, and is freely and widely available in retailoutlets. It is a well researched herb, with a longhistory of traditional usage and has an excellent safety profile. One four week clinical trial to assess safetydemonstrated an absence of side effects. Thus, itis unlikely that you will experience any adverse effects. It is recommended that the tablets be taken after food.Research report on Brahmi - Bacopa Monnieri Southern Cross University, NSW, Australia Department of Biological Chemistry, Medical Chemistry and Molecular Biology, University of Catania, v.le A. Doria 6, 95125, Catania, & Department of Experimental Pharmacology, University of Naples ‘Federico II’, via D. Montesano 49, 80131, Naples (ITALY) By Alessandra Russo, Francesca Borrellib, Agata Campisia, Rosaria Acquavivaa, Giuseppina Racitia, Angelo VanellaaThere is growing evidence that high concentrations of nitric oxide (NO), generated by activated astrocytes,might be involved in a variety of neurodegenerative diseases, such as Alzheimers disease, ischemia andepilepsy. It has recently been suggested that glial cells may produce NO under superoxide radical stimulationby enzyme-independent mechanism. This suggests that also natural antioxidants may have therapeuticalrelevance in neurodegenerative diseases. Studies of Bhattacharya et al. have evidenced that Bacopamonniera (BM) (family Scrophulariaceae), an Ayurvedic medicinal plant clinically used for memoryenhancing, epilepsy, insomnia and as a mild sedative, is able to reduce the memory-dysfunction in ratmodels of Alzheimers disease, but the molecular mechanisms of this action are yet to be determined. In thepresent study, we examined the effect of a methanolic extract of BM on toxicity induced by the nitric oxidedonor, S-nitroso-N-acetyl-penicillamine (SNAP), in culture of purified rat astrocytes. Our results indicatethat, after 18 h of treatment, SNAP induced an increase in the production of reactive species, but did notinduce the rupture of cellular membrane. Conversely, this NO donor induced a fragmentation of genomic DNAcompared to control astrocytes. The extract of BM inhibited the formation of reactive species and DNAdamage in a dose dependent manner. This data supports the traditional use of BM and indicatesthat this medicinal plant has a therapeutic potential in treatment or prevention of neurologicaldiseases.
  • Click here for for the above research report page www.bacopa-monnieri.us Journal of Alzheimers Disease, Volume 9, Number 3 Year: 2006 Authors: Leigh A. Holcomb: Central Texas Veterans Health Care System Neuropsychiatry Research Program, Temple, TX, USAAngie R. Hitt: Department of Neurology, Texas A&M University System HSC College of Medicine, Temple, TX, USAKeith A. Young: Department of Psychiatry and Behavioral Science, Texas A&M University System HSC College of Medicine, Temple, TXMark Riggs: Department of Research & Education, Scott and White Clinic, Texas A&M University System HSC College of Medicine, Temple, TX, USABacopa monniera extract reduces amyloid levels in PSAPP mice: PSAPP mice expressing the"Swedish" amyloid precursor protein and M146L presenilin-1 mutations are a well-characterized model forspontaneous amyloid plaque formation. Bacopa monniera has a long history of use in India as an anti-agingand memory-enhancing ethnobotanical therapy. To evaluate the effect of Bacopa monniera extract (BME)on beta-amyloid (Aß) pathology in PSAPP mice, two doses of BME (40 or 160 mg/kg/day) wereadministered starting at 2 months of age for either 2 or 8 months. Our present data suggests that BMElowers Aß 1-40 and 1-42 levels in cortex by as much as 60% , and reverses Y-maze performance andopen field hyperlocomotion behavioral changes present in PSAPP mice. The areas encompassed by CongoRed-positive fibrillar amyloid deposits, however, were not altered by BME treatment. The data suggest thatBME has potential application in Alzheimers disease therapeutics.Click here for for the above research report page www.bacopa-monnieri.us